Public recall detail

Accel-Ondansetron ODT 4 & 8 mg: Data integrity concerns with product's bioequivalence data that could lead to incorrect dosing.

2024-06-10

medium
Recall Safety notice
Quick summary

Quick summary: Accel-Ondansetron ODT 4 & 8 mg: Data integrity concerns with product's bioequivalence data that could lead to incorrect dosing.. Date: 2024-06-10.

Recommended action

Recommended action: compare your product with the official notice and follow the instructions published by the official source.

Recall details

Quick summary: Accel-Ondansetron ODT 4 & 8 mg: Data integrity concerns with product's bioequivalence data that could lead to incorrect dosing.. Date: 2024-06-10.

Official details

Affected product details

Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.

BrandAccel Pharma Inc., Accel-Ondansetron ODT 4 mg, Accel-Ondansetron ODT 8 mg
ProductAccel-Ondansetron ODT 4 & 8 mg
IssueHealth products - Product quality
Recall classType I
IdentificationRA-75630

Affected products

BrandAccel-Ondansetron ODT 4 mg
ProductAccel-Ondansetron ODT 4 mg
DIN / NPN / authorizationDIN 02535319
Dosage formTablet (Orally Disintegrating)
StrengthOndansetron 4 mg
LotCDX00123
BrandAccel-Ondansetron ODT 8 mg
ProductAccel-Ondansetron ODT 8 mg
DIN / NPN / authorizationDIN 02535327
Dosage formTablet (Orally Disintegrating)
StrengthOndansetron 8 mg
LotCEA00123

Issue

UPDATE: June 17, 2025 - Accel Pharma can resume sale of undistributed unit of lots CDX00123 & CEA00123 after bioequivalence test data confirm Accel-Ondansetron ODT is safe and effective to use. Data integrity concerns with product's bioequivalence data that could lead to incorrect dosing.

What you should do

  • Return the affected products to your local pharmacy for a replacement, and for proper disposal. If you are unsure whether your product is affected, check with your pharmacy.
  • Consult a health care professional if you have used the affected product and you have health concerns.
  • Report any health product-related side effects or complaints to Health Canada.
  • Contact the companies if you have questions about their recall: Accel Pharma Inc., by contacting Betty Cory at Accel Quality Assurance by calling 416-271-4775, or by email at bcory@regxia.com
  • Accel Pharma Inc., by contacting Betty Cory at Accel Quality Assurance by calling 416-271-4775, or by email at bcory@regxia.com
Additional official information
AudienceGeneral public Healthcare Industry
CategoryHealth products - Drugs
CompaniesAccel Pharma Inc. 119 Labrosse Ave, Pointe-Claire QC, H9R 1A3
Published byHealth Canada
Recall classType I
Alert / recall typeHealth product recall
Identification numberRA-75630
Background{}
CompaniesAccel Pharma Inc. 119 Labrosse Ave, Pointe-Claire QC, H9R 1A3
AudiencesGeneral public Healthcare Industry
Source updated2025-06-18

Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.

Starting...

Related recalls

Similar recalls and safety notices.

Loading related recalls...